Use of Low-Molecular-Weight Heparin and Peak anti-Xa Monitoring In Severe SARS-CoV-2 Disease: A Brief Report. (December 2021)

• Record Type: Journal Article
• Authors: Toor, Rebecca; Zamora, Francis J.; Fatteh, Naaz; Drexler, Nathan; Lozada, Jose
• Is Part Of: Hospital pharmacy. Volume 56:Number 6(2021)
• Page Start: 640
• Page End: 645
• Publication Date: 2021-12
• Subjects: anticoagulation -- SARS-COV-2 -- severe -- peak anti-Xa level -- D-dimer; Hospital pharmacies -- Periodicals; Pharmacy Service, Hospital; Hospital pharmacies; Periodicals; Periodicals; 615.1
• DOI: 10.1177/0018578720954154
• Languages: English
• ISSNs: 0018-5787

Abstract

In 2019, a novel coronavirus was identified in Wuhan, China. This strain was classified as a pandemic in early 2020 by the World Health Organization (WHO), rapidly reaching millions of cases worldwide and overwhelming intensive care units. One distinct feature identified in severe SARS-CoV-2 is abnormal and complex coagulation and hematologic abnormalities, including significantly elevated D-dimer and fibrin/fibrinogen values possibly increasing morbidity and mortality in this patient population. Aggressive anticoagulation therapy with appropriate peak anti-Xa level monitoring has produce satisfactory results at our institution. Our intent is to present a case series of our strategy to highlight the benefits of this approach.